Depression and Anxiety in CKD: Providing Individualized Care
Anxiety and depression are highly prevalent in chronic kidney disease. In recent years, we’ve learned that response to antidepressants is different in patients with kidney disease. This, coupled with altered medication risk profiles due to declining kidney function, makes management of anxiety and depression a considerable challenge. This module provides an overview of pharmacologic and non-pharmacologic treatment options for anxiety and depression unique to patients with kidney disease.
By the end of this module, learners will be able to:
- Describe prevalence of depression compared to the general population
- Review risk factors for depression
- Discuss non-pharmacologic and preferred pharmacologic options for treating depression and anxiety
- Review the pharmacokinetics and pharmacodynamics of commonly used antidepressants
- Create a treatment plan to select, initiate, adjust, and/or modify pharmacologic agents used in management of depression and anxiety
The following planners and presenters have disclosed a financial relationship with an ineligible company:
- Wendy St. Peter, PharmD, FCCP, FASN, FNKF - Consultant [GSK, Boehringer-Ingelheim/Lilly, Bayer]
- Marissa Battistella, PharmD - Speakers Bureau: Otsuka Canada- honorarium for presentations
- Patrick Gee, PhD - Speaker's Bureau: Boehringer Ingelheim, UCAR & eGFR blood test, March 2024
- Max Smith, PharmD - Grants/Research Support: Kailos Genetics, Inc. - funds to institution - support ended July 2023
There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.
All relevant financial relationships have been mitigated.
In support of improving patient care, this activity is planned and implemented by The National Center for Interprofessional Practice and Education Office of Interprofessional Continuing Professional Development (OICPD). The OICPD is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians: The National Center for Interprofessional Practice and Education designates this live activity for .75 hours AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with their participation.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
Nurses: Participants will be awarded .75 contact hours of credit for attendance in this module.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
Pharmacists: This activity is approved for .75 contact hours. UAN is JA4008105-9999-24-118-H01-P.
IPCE: This activity was planned by and for the healthcare team, and learners will receive Interprofessional Continuing Education (IPCE) credits for learning and change.
